$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

소아청소년 코로나바이러스감염증-19의 치료: 치료 약제를 중심으로
Therapeutics in the Treatment of COVID-19 for Children and Adolescents 원문보기

Pediatric infection and vaccine: PIV, v.29 no.1, 2022년, pp.1 - 15  

최수한 (부산대학교병원 소아청소년과) ,  최재홍 (제주대학교병원 소아청소년과) ,  윤기욱 (서울대학교병원 소아청소년과)

초록
AI-Helper 아이콘AI-Helper

소아청소년에서 코로나바이러스감염증-19 (coronavirus disease 2019 [COVID-19])은 대부분 경증이며 특별한 치료없이 호전될 수 있다. 하지만 일부 소아청소년 COVID-19 환자에서는 중증 또는 위중증으로 진행할 수 있다. 소아청소년 COVID-19 치료 약제에 대한 임상 데이터는 제한적이지만, 중증 및 위중증 COVID-19 소아청소년 환자에서 사용 가능한 약제들은 있다. 본 종설에서는 COVID-19 치료 약제 중 항바이러스제와 면역조절제에 중점을 두고 임상 데이터와 소아청소년에 대한 권고 사항들을 논의하였다.

Abstract ▼ AI-Helper 아이콘AI-Helper

Coronavirus disease 2019 (COVID-19) presents as a mild-to-moderate respiratory illness in most children. However, a small proportion of children with COVID-19 develop severe or critical illnesses. Although pediatric clinical trials for the treatment of COVID-19 are sparse, some drugs are available f...

주제어

#COVID-19   #Therapeutics   #Child   #Adolescent  

참고문헌 (51)

  1. Fraile Navarro D, Tendal B, Tingay D, Vasilunas N, Anderson L, Best J, et al. Clinical care of children and adolescents with COVID-19: recommendations from the National COVID-19 Clinical Evidence Taskforce. Med J Aust 2021;mja2.51305. 

  2. Lee H, Choi S, Park JY, Jo DS, Choi UY, Lee H, et al. Analysis of critical COVID-19 cases among children in Korea. J Korean Med Sci 2022;37:e13. 

    상세보기

  3. Woodruff RC, Campbell AP, Taylor CA, Chai SJ, Kawasaki B, Meek J, et al. Risk factors for severe COVID-19 in children. Pediatrics 2021;e2021053418. 

  4. Kompaniyets L, Agathis NT, Nelson JM, Preston LE, Ko JY, Belay B, et al. Underlying medical conditions associated with severe COVID-19 illness among children. JAMA Netw Open 2021;4:e2111182. 

    상세보기

  5. Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, et al. Multicenter interim guidance on use of antivirals for children with coronavirus disease 2019/severe acute respiratory syndrome coronavirus 2. J Pediatric Infect Dis Soc 2021;10:34-48. 

  6. Dulek DE, Fuhlbrigge RC, Tribble AC, Connelly JA, Loi MM, El Chebib H, et al. Multidisciplinary guidance regarding the use of immunomodulatory therapies for acute coronavirus disease 2019 in pediatric patients. J Pediatric Infect Dis Soc 2020;9:716-37. 

  7. National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing COVID-19 [Internet]. London: NICE; 2021 [cited 2022 Feb 27]. Available from: https://www.nice.org.uk/guidance/ng191/chapter/Recommendations 

  8. National Institutes of Health (NIH). Coronavirus disease 2019 (COVID-19) treatment guidelines [Internet]. Bethesda: NIH; 2022 [cited 2022 Jan 24]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/. 

  9. World Health Organization (WHO). Therapeutics and COVID-19: living guideline [Internet]. Geneva: WHO; 2022 [cited 2022 Jan 21]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.3. 

  10. Infectious Diseases Society of America (IDSA). IDSA guidelines on the treatment and management of patients with COVID-19 [Internet]. Arlington: IDSA; 2022 [cited 2022 Jan 21]. Available from: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. 

  11. Hall MD, Anderson JM, Anderson A, Baker D, Bradner J, Brimacombe KR, et al. Report of the National Institutes of Health SARS-CoV-2 antiviral therapeutics summit. J Infect Dis 2021;224:S1-21. 

    상세보기

  12. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed antiviral drugs for COVID-19 - Interim WHO Solidarity Trial results. N Engl J Med 2021;384:497-511. 

    상세보기

  13. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 - final report. N Engl J Med 2020;383:1813-26. 

    상세보기

  14. Spinner CD, Gottlieb RL, Criner GJ, Arribas Lopez JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 2020;324:1048-57. 

    상세보기

  15. Goldman JD, Lye DC, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe COVID-19. N Engl J Med 2020;383:1827-37. 

    상세보기

  16. Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early remdesivir to prevent progression to severe COVID-19 in outpatients. N Engl J Med 2022;386:305-15. 

    상세보기

  17. Gilead Sciences. Study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of remdesivir (GS-5734 TM ) in participants from birth to < 18 years of age with coronavirus disease 2019 (COVID-19) (CARAVAN) [Internet]. Bethesda: National Institutes of Health (NIH); 2021 [cited 2022 Jan 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT04431453?termremdesivir&condCOVID-19&age0&draw2&rank1. 

  18. Goldman DL, Aldrich ML, Hagmann SH, Bamford A, Camacho-Gonzalez A, Lapadula G, et al. Compassionate use of remdesivir in children with severe COVID-19. Pediatrics 2021;147:e2020047803. 

    상세보기

  19. Mendez-Echevarria A, Perez-Martinez A, Gonzalez Del Valle L, Ara MF, Melendo S, Ruiz de Valbuena M, et al. Compassionate use of remdesivir in children with COVID-19. Eur J Pediatr 2021;180:1317-22. 

    상세보기

  20. National COVID-19 Clinical Evidence Taskforce (AU). Australian guidelines for the clinical care of people with COVID-19 [Internet]. Melbourne: National COVID-19 Clinical Evidence Taskforce; 2022 [cited 2022 Jan 21]. Available from: https://covid19evidence.net.au/#living-guidelines. 

  21. U.S. Food and Drug Administration (FDA). FDA takes actions to expand use of treatment for outpatients with mild-to-moderate COVID-19 [Internet]. Silver Spring: FDA; 2022 [cited 2022 Jan 24]. Available from: https://www.fda.gov/news-events/press-announcements/fda-takes-actions-expand-use-treatment-outpatients-mild-moderate-covid-19. 

  22. National Institutes of Health (NIH). Coronavirus disease 2019 (COVID-19) treatment guidelines. Special considerations in children [Internet]. Bethesda: NIH; 2021 [cited 2022 Jan 14]. Available from: https://www.covid19treatmentguidelines.nih.gov/special-populations/children/. 

  23. Korea Disease Control and Prevention Agency (KDCA). Guidance on the use of COVID-19 treatment [Internet]. Cheongju: KDCA; 2022 [cited 2022 Feb 27]. Available from: http://ncov.mohw.go.kr/shBoardView.do?brdId2&brdGubun24&ncvContSeq5314. 

  24. Korea Ministry of Food and Drug Safety (MFDS). Changes in the approval of remdesivir [Internet]. Cheongju: MFDS; 2022 [cited 2022 Jan 14]. Available from: https://www.mfds.go.kr/brd/m_99/view.do?seq46060. 

  25. Korea Ministry of Food and Drug Safety (MFDS). Approval for additional emergency use of remdesivir [Internet]. Cheongju: MFDS; 2022 [cited 2022 Jan 25]. Available from: https://www.mfds.go.kr/brd/m_99/view.do?seq46086. 

  26. U.S. Food and Drug Administration (FDA). Fact sheet for healthcare providers: emergency use authorization for paxlovid [Internet]. Silver Spring: FDA; 2021 [cited 2022 Jan 14]. Available from: https://www.fda.gov/media/155050/download. 

  27. Pourkarim F, Pourtaghi-Anvarian S, Rezaee H. Molnupiravir: a new candidate for COVID-19 treatment. Pharmacol Res Perspect 2022;10:e00909. 

    상세보기

  28. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med 2022;386:509-20. 

    상세보기

  29. U.S. Food and Drug Administration (FDA). Fact sheet for healthcare providers: emergency use authorization for molnupiravir [Internet]. Silver Spring: FDA; 2021 [cited 2022 Jan 14]. Available from: https://www.fda.gov/media/155054/download. 

  30. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-4. 

  31. Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA 2020;324:1317-29. 

    상세보기

  32. Dequin PF, Heming N, Meziani F, Plantefeve G, Voiriot G, Badie J, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA 2020;324:1298-306. 

    상세보기

  33. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JA, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 2020;324:1330-41. 

    상세보기

  34. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA 2020;324:1307-16. 

    상세보기

  35. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021;384:693-704. 

    상세보기

  36. Jeronimo CM, Farias ME, Val FF, Sampaio VS, Alexandre MA, Melo GC, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis 2021;72:e373-81. 

    상세보기

  37. U.S. Food and Drug Administration (FDA). Fact sheet for healthcare providers: emergency use authorization for Actemra (tocilizumab) [Internet]. Silver Spring: FDA; 2021 [cited 2022 Jan 21]. Available from: https://www.fda.gov/media/150321/download. 

  38. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021;397:1637-45. 

  39. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JP, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA 2021;326:499-518. 

    상세보기

  40. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med 2021;384:795-807. 

  41. Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med 2021;9:1407-18. 

    상세보기

  42. U.S. Food and Drug Administration (FDA). Fact sheet for healthcare providers: emergency use authorization of baricitinib [Internet]. Silver Spring: FDA; 2021 [cited 2022 Jan 21]. Available from: https://www.fda.gov/media/143823/download. 

  43. Dougan M, Azizad M, Mocherla B, Gottlieb RL, Chen P, Hebert C, et al. A randomized, placebocontrolled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. Clin Infect Dis 2021;ciab912. 

  44. Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. N Engl J Med 2021;385:1382-92. 

    상세보기

  45. Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med 2021;385:1941-50. 

    상세보기

  46. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGEN-COV antibody combination and outcomes in outpatients with COVID-19. N Engl J Med 2021;385:e81. 

    상세보기

  47. Mak G, Dassner AM, Hammer BM, Hanisch BR. Safety and tolerability of monoclonal antibody therapies for treatment of COVID-19 in pediatric patients. Pediatr Infect Dis J 2021;40:e507-9. 

    상세보기

  48. American Academy of Pediatrics (AAP). Management of strategies in children and adolescents with mild to moderate COVID-19 [Internet]. Itasca: AAP; 2022 [cited 2022 Jan 25]. Available from: https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/outpatient-covid-19-management-strategies-in-children-and-adolescents/. 

  49. U.S. Food and Drug Administration (FDA). Fact sheet for healthcare providers: emergency use authorization of bamlanivimab and etesevimab [Internet]. Silver Spring: FDA; 2021 [cited 2022 Jan 25]. Available from: https://www.fda.gov/media/145802/download. 

  50. Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, Culap K, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 2022;602:664-70. 

  51. U.S. Food and Drug Administration (FDA). Coronavirus (COVID-19) update: FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the Omicron variant [Internet]. Silver Spring: FDA; 2022 [cited 2022 Jan 25]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron. 

관련 콘텐츠

오픈액세스(OA) 유형

GOLD

오픈액세스 학술지에 출판된 논문

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로